This may be a treatment-relevant finding since JAK2-kinase rearranged ALL with fusions of JAK2 to ATF7IP, EBF1, PAX5, SSBP2, RNPC3, GOLGA5, PCM1 and their effective inhibition by treatment with the JAK inhibitor ruxolitinib have been described previously in anecdotal cases [25,26,27,28]. The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.